Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 4/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11229344 | 0.86 | GABBR2 (0.53) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL13564512 | 0.79 | FFAR1 (0.57) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL6379988 | 0.79 | FFAR1 (0.57) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL1646356 | 0.78 | L3MBTL1 (0.54) | LMNACYP2C9CYP2C19KMT2AMAPT | |
| SCHEMBL16249736 | 0.78 | GABBR2 (0.61) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL3665382 | 0.76 | FOLH1 (0.47) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL3872457 | 0.76 | ESR1 (0.59) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL3724690 | 0.76 | ESR1 (0.59) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL3879432 | 0.76 | ESR1 (0.59) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL28801346 | 0.75 | GABBR2 (0.72) | GABBR2GABBR1LMNACYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208882-A1 | Organic Compounds | DANAHAY HENRY LUKE (GB) | 2012-08-16 | — | — | US | disclosed |
| EP-2305639-A2 | Organic compounds | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2253612-A1 | Organic compounds | Novartis AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20090203777-A1 | ORGANIC COMPOUNDS | MAAS, JANET CATHERINE (GB) | 2009-08-13 | — | — | US | disclosed |
| EP-1874726-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108643-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-4021472-A | ANTIPLASMIN AND ANTITRYPSIN | ONO PHARMACEUTICAL CO., LTD. (JA) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208882-A1 | Organic Compounds | CFTR, OTC, ASIC1 | GABBR2 577/4885GABBR1 702/4885LMNA 4105/4885 |
| US-20090203777-A1 | ORGANIC COMPOUNDS | CFTR, OTC, ASIC1 | GABBR2 577/4885GABBR1 702/4885LMNA 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.